| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Enterovirus Infections | 7 | 2018 | 404 | 2.23 | Why? |
| Enterovirus A, Human | 6 | 2018 | 180 | 2.07 | Why? |
| Ebola Vaccines | 3 | 2017 | 126 | 1.34 | Why? |
| Immunogenicity, Vaccine | 6 | 2021 | 4624 | 1.14 | Why? |
| Vaccines, Inactivated | 9 | 2021 | 1562 | 1.11 | Why? |
| Human papillomavirus 18 | 2 | 2019 | 36 | 1.00 | Why? |
| Immunization Schedule | 7 | 2020 | 1305 | 0.99 | Why? |
| Human papillomavirus 16 | 2 | 2019 | 95 | 0.93 | Why? |
| Viral Vaccines | 7 | 2020 | 7560 | 0.88 | Why? |
| Hepatitis B Surface Antigens | 5 | 2019 | 305 | 0.85 | Why? |
| Hand, Foot and Mouth Disease | 3 | 2018 | 115 | 0.83 | Why? |
| Bunyaviridae Infections | 2 | 2019 | 107 | 0.79 | Why? |
| Hepatitis B e Antigens | 2 | 2018 | 99 | 0.76 | Why? |
| Double-Blind Method | 13 | 2021 | 5988 | 0.75 | Why? |
| Hepatitis B Vaccines | 4 | 2017 | 245 | 0.72 | Why? |
| Vaccines, Synthetic | 7 | 2021 | 3231 | 0.71 | Why? |
| Remission, Spontaneous | 1 | 2018 | 186 | 0.70 | Why? |
| Peptide Library | 1 | 2020 | 564 | 0.68 | Why? |
| Phlebotomus Fever | 1 | 2017 | 44 | 0.67 | Why? |
| Hemorrhagic Fever, Ebola | 3 | 2017 | 1475 | 0.66 | Why? |
| Haemophilus Vaccines | 1 | 2017 | 76 | 0.66 | Why? |
| Papillomavirus Vaccines | 2 | 2019 | 405 | 0.66 | Why? |
| Mumps | 1 | 2018 | 110 | 0.64 | Why? |
| Measles-Mumps-Rubella Vaccine | 1 | 2018 | 282 | 0.56 | Why? |
| Pneumonia, Pneumococcal | 1 | 2017 | 251 | 0.56 | Why? |
| Meningococcal Vaccines | 1 | 2017 | 225 | 0.54 | Why? |
| Papillomavirus Infections | 2 | 2019 | 861 | 0.52 | Why? |
| Seroconversion | 4 | 2020 | 2515 | 0.50 | Why? |
| China | 26 | 2021 | 50654 | 0.49 | Why? |
| Adenoviridae | 4 | 2020 | 1151 | 0.47 | Why? |
| Pneumococcal Vaccines | 1 | 2017 | 571 | 0.46 | Why? |
| Hepatitis B virus | 2 | 2018 | 882 | 0.46 | Why? |
| Hepatitis B, Chronic | 1 | 2018 | 616 | 0.45 | Why? |
| Antibodies, Neutralizing | 12 | 2021 | 25288 | 0.45 | Why? |
| Pneumococcal Infections | 1 | 2017 | 562 | 0.44 | Why? |
| Hepatitis B | 5 | 2019 | 888 | 0.42 | Why? |
| Immunization, Secondary | 2 | 2016 | 1649 | 0.40 | Why? |
| Antibodies, Viral | 18 | 2021 | 51949 | 0.36 | Why? |
| Thrombocytopenia | 2 | 2019 | 2093 | 0.34 | Why? |
| Adolescent | 20 | 2021 | 86841 | 0.31 | Why? |
| Hepatitis B Antibodies | 2 | 2017 | 142 | 0.29 | Why? |
| Antibody Formation | 3 | 2017 | 4038 | 0.29 | Why? |
| Vaccines, Conjugate | 2 | 2017 | 328 | 0.29 | Why? |
| Young Adult | 18 | 2021 | 93724 | 0.28 | Why? |
| Influenza, Human | 5 | 2019 | 10779 | 0.28 | Why? |
| Placebos | 2 | 2018 | 629 | 0.28 | Why? |
| Infant | 14 | 2020 | 30274 | 0.27 | Why? |
| Child, Preschool | 13 | 2020 | 36283 | 0.25 | Why? |
| Genetic Vectors | 3 | 2020 | 1600 | 0.25 | Why? |
| Healthy Volunteers | 2 | 2020 | 1444 | 0.25 | Why? |
| Enterovirus | 2 | 2018 | 402 | 0.24 | Why? |
| Vaccines | 1 | 2021 | 3692 | 0.23 | Why? |
| Influenza Vaccines | 3 | 2017 | 2941 | 0.23 | Why? |
| Antibodies, Monoclonal | 2 | 2020 | 8041 | 0.23 | Why? |
| Female | 37 | 2021 | 380317 | 0.23 | Why? |
| Adult | 25 | 2021 | 244371 | 0.22 | Why? |
| Male | 33 | 2021 | 367725 | 0.22 | Why? |
| Humans | 55 | 2021 | 930598 | 0.21 | Why? |
| Enterovirus B, Human | 2 | 2018 | 124 | 0.21 | Why? |
| Viral Hepatitis Vaccines | 2 | 2017 | 58 | 0.21 | Why? |
| Escherichia coli Vaccines | 1 | 2019 | 7 | 0.20 | Why? |
| Influenza A Virus, H1N1 Subtype | 2 | 2017 | 2984 | 0.20 | Why? |
| Sequence Analysis, Protein | 1 | 2020 | 309 | 0.20 | Why? |
| Cyclopentanes | 1 | 2019 | 55 | 0.20 | Why? |
| Quaternary Ammonium Compounds | 1 | 2021 | 136 | 0.20 | Why? |
| Fever | 1 | 2017 | 7795 | 0.20 | Why? |
| Ebolavirus | 2 | 2016 | 834 | 0.20 | Why? |
| Poliovirus Vaccine, Inactivated | 1 | 2019 | 72 | 0.19 | Why? |
| Poliovirus | 1 | 2019 | 109 | 0.19 | Why? |
| Hemagglutination Inhibition Tests | 3 | 2017 | 191 | 0.18 | Why? |
| Coxsackievirus Infections | 1 | 2018 | 71 | 0.18 | Why? |
| Nucleocapsid Proteins | 2 | 2021 | 3120 | 0.18 | Why? |
| Chitosan | 1 | 2021 | 196 | 0.18 | Why? |
| Bunyaviridae | 1 | 2017 | 22 | 0.18 | Why? |
| Phlebovirus | 1 | 2019 | 106 | 0.18 | Why? |
| Neisseria meningitidis, Serogroup A | 1 | 2017 | 5 | 0.18 | Why? |
| Caspase 1 | 1 | 2018 | 149 | 0.18 | Why? |
| DNA, Circular | 1 | 2017 | 26 | 0.18 | Why? |
| Tick Bites | 1 | 2017 | 34 | 0.17 | Why? |
| Haemophilus influenzae type b | 1 | 2017 | 30 | 0.17 | Why? |
| Injections, Intramuscular | 1 | 2020 | 800 | 0.17 | Why? |
| Immunoglobulin Fab Fragments | 1 | 2020 | 556 | 0.17 | Why? |
| Circovirus | 1 | 2017 | 53 | 0.17 | Why? |
| Middle Aged | 20 | 2021 | 270681 | 0.17 | Why? |
| Neisseria meningitidis, Serogroup C | 1 | 2017 | 46 | 0.17 | Why? |
| Neuraminidase | 1 | 2019 | 289 | 0.17 | Why? |
| Enterovirus D, Human | 1 | 2018 | 96 | 0.17 | Why? |
| Vaccines, Combined | 1 | 2017 | 67 | 0.17 | Why? |
| Mass Screening | 1 | 2017 | 8005 | 0.16 | Why? |
| Viral Load | 6 | 2020 | 15850 | 0.16 | Why? |
| DNA, Single-Stranded | 1 | 2017 | 95 | 0.16 | Why? |
| Age Factors | 5 | 2020 | 21039 | 0.16 | Why? |
| Foot-and-Mouth Disease | 1 | 2016 | 35 | 0.16 | Why? |
| Nucleic Acid Hybridization | 1 | 2017 | 140 | 0.16 | Why? |
| Enzyme-Linked Immunosorbent Assay | 4 | 2020 | 7868 | 0.16 | Why? |
| Clinical Trials, Phase III as Topic | 1 | 2021 | 782 | 0.16 | Why? |
| Hemagglutinins | 1 | 2017 | 143 | 0.16 | Why? |
| Spike Glycoprotein, Coronavirus | 4 | 2021 | 37182 | 0.16 | Why? |
| Central Nervous System Infections | 1 | 2018 | 158 | 0.16 | Why? |
| Pyroptosis | 1 | 2018 | 168 | 0.16 | Why? |
| Adjuvants, Immunologic | 2 | 2021 | 1709 | 0.16 | Why? |
| Sierra Leone | 1 | 2016 | 267 | 0.16 | Why? |
| Tetanus Toxoid | 1 | 2017 | 136 | 0.15 | Why? |
| Phosphoproteins | 3 | 2021 | 4346 | 0.15 | Why? |
| Antibody Affinity | 1 | 2020 | 1078 | 0.15 | Why? |
| Time Factors | 5 | 2020 | 31397 | 0.15 | Why? |
| Poliomyelitis | 1 | 2019 | 263 | 0.15 | Why? |
| Immunoglobulins | 2 | 2017 | 811 | 0.15 | Why? |
| Vaccination | 7 | 2020 | 19050 | 0.15 | Why? |
| Disease Outbreaks | 2 | 2020 | 27595 | 0.14 | Why? |
| Guanidines | 1 | 2019 | 499 | 0.14 | Why? |
| Influenza A Virus, H7N9 Subtype | 1 | 2019 | 415 | 0.14 | Why? |
| Genes, Viral | 1 | 2020 | 1428 | 0.14 | Why? |
| Geography | 2 | 2019 | 1801 | 0.14 | Why? |
| Nucleic Acid Amplification Techniques | 2 | 2020 | 3388 | 0.14 | Why? |
| Hepatitis B Core Antigens | 1 | 2014 | 76 | 0.13 | Why? |
| Chemokines | 1 | 2020 | 1095 | 0.13 | Why? |
| Ecosystem | 1 | 2019 | 776 | 0.13 | Why? |
| Agriculture | 1 | 2017 | 367 | 0.13 | Why? |
| Climate | 2 | 2019 | 557 | 0.13 | Why? |
| Reverse Transcription | 1 | 2017 | 673 | 0.13 | Why? |
| Pharynx | 2 | 2020 | 1544 | 0.13 | Why? |
| Mycoses | 1 | 2020 | 589 | 0.13 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 3 | 2019 | 1261 | 0.13 | Why? |
| Hepatitis E virus | 1 | 2017 | 306 | 0.13 | Why? |
| Antibodies, Bacterial | 1 | 2017 | 510 | 0.12 | Why? |
| Post-Exposure Prophylaxis | 1 | 2017 | 472 | 0.12 | Why? |
| Single-Blind Method | 1 | 2017 | 1283 | 0.12 | Why? |
| Aged, 80 and over | 6 | 2021 | 88759 | 0.12 | Why? |
| Hepatitis E | 1 | 2017 | 319 | 0.12 | Why? |
| Immunoglobulin M | 2 | 2020 | 9091 | 0.12 | Why? |
| Drug Resistance, Viral | 1 | 2019 | 1083 | 0.12 | Why? |
| T-Lymphocytes | 2 | 2020 | 6670 | 0.12 | Why? |
| Streptococcus pneumoniae | 1 | 2017 | 827 | 0.12 | Why? |
| Syndrome | 1 | 2017 | 1310 | 0.12 | Why? |
| Glycoproteins | 1 | 2016 | 615 | 0.11 | Why? |
| Treatment Failure | 1 | 2017 | 2106 | 0.11 | Why? |
| Infectious Disease Transmission, Vertical | 3 | 2017 | 5164 | 0.11 | Why? |
| Pandemics | 9 | 2021 | 389249 | 0.11 | Why? |
| Child | 8 | 2020 | 70012 | 0.11 | Why? |
| Follow-Up Studies | 3 | 2018 | 17020 | 0.10 | Why? |
| DNA, Viral | 2 | 2017 | 2521 | 0.10 | Why? |
| Digestive System Diseases | 1 | 2015 | 378 | 0.10 | Why? |
| Aged | 10 | 2021 | 215776 | 0.10 | Why? |
| Alum Compounds | 1 | 2009 | 210 | 0.09 | Why? |
| Hemagglutinins, Viral | 1 | 2009 | 176 | 0.09 | Why? |
| Physical Examination | 1 | 2015 | 755 | 0.09 | Why? |
| Prospective Studies | 6 | 2018 | 43301 | 0.09 | Why? |
| Coronavirus Infections | 7 | 2021 | 253789 | 0.09 | Why? |
| Epitopes | 1 | 2020 | 4113 | 0.09 | Why? |
| Feasibility Studies | 1 | 2017 | 3467 | 0.09 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.08 | Why? |
| Rabies virus | 1 | 2007 | 92 | 0.08 | Why? |
| Rabies Vaccines | 1 | 2007 | 106 | 0.08 | Why? |
| Immunity, Cellular | 1 | 2020 | 3614 | 0.08 | Why? |
| RNA, Messenger | 1 | 2021 | 5131 | 0.08 | Why? |
| Immunoglobulin G | 2 | 2020 | 21571 | 0.08 | Why? |
| Dogs | 2 | 2019 | 2529 | 0.08 | Why? |
| Bacterial Infections | 1 | 2020 | 2229 | 0.08 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.08 | Why? |
| Computer Simulation | 1 | 2021 | 4982 | 0.08 | Why? |
| Public Health Surveillance | 1 | 2019 | 3129 | 0.07 | Why? |
| Immunity, Humoral | 1 | 2020 | 4849 | 0.07 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.07 | Why? |
| Nanoparticles | 1 | 2017 | 2040 | 0.07 | Why? |
| Influenza A virus | 1 | 2017 | 2234 | 0.07 | Why? |
| Health Resources | 1 | 2017 | 2592 | 0.07 | Why? |
| Databases, Factual | 1 | 2019 | 6248 | 0.07 | Why? |
| Incidence | 2 | 2017 | 25622 | 0.07 | Why? |
| Models, Biological | 1 | 2021 | 4907 | 0.06 | Why? |
| Animals | 6 | 2019 | 78931 | 0.06 | Why? |
| Biomarkers | 3 | 2021 | 23361 | 0.06 | Why? |
| Virus Diseases | 1 | 2020 | 3779 | 0.06 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2017 | 4545 | 0.06 | Why? |
| Drug Repositioning | 1 | 2021 | 5683 | 0.06 | Why? |
| Logistic Models | 1 | 2017 | 9089 | 0.06 | Why? |
| Seasons | 1 | 2015 | 4071 | 0.06 | Why? |
| Cats | 1 | 2007 | 1890 | 0.05 | Why? |
| Viral Proteins | 1 | 2019 | 7370 | 0.05 | Why? |
| Disease Models, Animal | 1 | 2018 | 10998 | 0.05 | Why? |
| Acids, Carbocyclic | 1 | 2019 | 27 | 0.05 | Why? |
| Contact Tracing | 1 | 2020 | 8448 | 0.05 | Why? |
| Coinfection | 1 | 2020 | 6820 | 0.05 | Why? |
| Cytomegalovirus Vaccines | 1 | 2018 | 6 | 0.05 | Why? |
| Recombinases | 1 | 2020 | 137 | 0.05 | Why? |
| Dose-Response Relationship, Radiation | 1 | 2019 | 133 | 0.05 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 1 | 2021 | 8843 | 0.05 | Why? |
| Antiviral Agents | 3 | 2021 | 41703 | 0.05 | Why? |
| Granulocyte Colony-Stimulating Factor | 1 | 2020 | 264 | 0.05 | Why? |
| DNA Fragmentation | 1 | 2018 | 67 | 0.05 | Why? |
| Serum Amyloid A Protein | 1 | 2020 | 211 | 0.05 | Why? |
| Chemokine CCL2 | 1 | 2020 | 389 | 0.04 | Why? |
| Cytokines | 1 | 2020 | 15010 | 0.04 | Why? |
| Animals, Newborn | 1 | 2018 | 350 | 0.04 | Why? |
| Seroepidemiologic Studies | 3 | 2018 | 10017 | 0.04 | Why? |
| Neuroblastoma | 1 | 2018 | 91 | 0.04 | Why? |
| Madin Darby Canine Kidney Cells | 1 | 2019 | 640 | 0.04 | Why? |
| Epidemics | 1 | 2017 | 6407 | 0.04 | Why? |
| Cloud Computing | 1 | 2019 | 214 | 0.04 | Why? |
| Disease Transmission, Infectious | 1 | 2020 | 9044 | 0.04 | Why? |
| Mice, Inbred BALB C | 2 | 2018 | 5814 | 0.04 | Why? |
| Respiratory Tract Infections | 1 | 2018 | 6817 | 0.04 | Why? |
| Host-Pathogen Interactions | 1 | 2017 | 11041 | 0.04 | Why? |
| Treatment Outcome | 3 | 2019 | 51732 | 0.04 | Why? |
| Interleukin-18 | 1 | 2018 | 328 | 0.04 | Why? |
| Vascular Endothelial Growth Factor A | 1 | 2020 | 604 | 0.04 | Why? |
| Intestine, Small | 1 | 2018 | 336 | 0.04 | Why? |
| Carrier State | 1 | 2007 | 2100 | 0.04 | Why? |
| Oseltamivir | 1 | 2019 | 583 | 0.04 | Why? |
| Risk Factors | 3 | 2019 | 71621 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Interleukin-1beta | 1 | 2018 | 992 | 0.03 | Why? |
| Spatio-Temporal Analysis | 1 | 2019 | 1182 | 0.03 | Why? |
| Gold | 1 | 2017 | 592 | 0.03 | Why? |
| Neurons | 1 | 2018 | 864 | 0.03 | Why? |
| Amino Acid Substitution | 1 | 2019 | 1706 | 0.03 | Why? |
| Limit of Detection | 1 | 2020 | 2698 | 0.03 | Why? |
| Infant, Newborn | 3 | 2018 | 23105 | 0.03 | Why? |
| Respiratory Mucosa | 1 | 2021 | 1522 | 0.03 | Why? |
| Escherichia coli | 1 | 2019 | 1547 | 0.03 | Why? |
| Viremia | 1 | 2018 | 1020 | 0.03 | Why? |
| Community Health Services | 1 | 2019 | 1000 | 0.03 | Why? |
| Cohort Studies | 3 | 2018 | 36005 | 0.02 | Why? |
| Surveys and Questionnaires | 1 | 2017 | 43792 | 0.02 | Why? |
| Gene Expression | 1 | 2019 | 3332 | 0.02 | Why? |
| Pregnancy | 3 | 2017 | 23879 | 0.02 | Why? |
| Sensitivity and Specificity | 2 | 2020 | 22971 | 0.02 | Why? |
| Virus Replication | 2 | 2019 | 14331 | 0.02 | Why? |
| Cells, Cultured | 1 | 2018 | 5835 | 0.02 | Why? |
| Evolution, Molecular | 1 | 2019 | 3691 | 0.02 | Why? |
| Fluorescent Antibody Technique | 1 | 2007 | 835 | 0.02 | Why? |
| Epidemiological Monitoring | 1 | 2017 | 3493 | 0.02 | Why? |
| Communicable Diseases, Emerging | 1 | 2019 | 2523 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.02 | Why? |
| Serologic Tests | 1 | 2017 | 4359 | 0.02 | Why? |
| Virus Internalization | 1 | 2021 | 7921 | 0.01 | Why? |
| Immunization, Passive | 1 | 2017 | 10067 | 0.01 | Why? |
| RNA, Viral | 2 | 2020 | 32276 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 11367 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2017 | 11304 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.01 | Why? |
| Health Policy | 1 | 2019 | 6242 | 0.01 | Why? |
| Phylogeny | 1 | 2017 | 13341 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2018 | 7330 | 0.01 | Why? |
| Retrospective Studies | 2 | 2020 | 105322 | 0.01 | Why? |
| Prevalence | 1 | 2019 | 25773 | 0.01 | Why? |
| Inflammation | 1 | 2018 | 13255 | 0.01 | Why? |
| Genome, Viral | 1 | 2017 | 13157 | 0.01 | Why? |
| Rural Population | 1 | 2007 | 2408 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2020 | 48226 | 0.01 | Why? |
| Pregnancy Complications, Infectious | 1 | 2017 | 11559 | 0.01 | Why? |
| Vero Cells | 1 | 2007 | 14117 | 0.01 | Why? |